Abstract

Highlights of LCA

Leber congenital amaurosis (LCA) is a rare retinal dystrophy with a prevalence at birth of approximately 1 in 80,000 (1). It is most often inherited in an autosomal-recessive manner. It typically becomes evident in the first year of life, with poor visual function often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia, and keratoconus. Profound visual impairment is usually present from birth.

LCA is caused by mutations in any one of at least 15 genes (2), and this accounts in part for its heterogeneous clinical presentation. To date, more than 400 mutations have been identified. Together, they account for approximately 70% of all LCA cases. The most frequently mutated genes are centrosomal protein 290 kDa (CEP290; also known as NPHP6), guanylate cyclase 2D (GUCY2D), and crumbs homolog 1 (CRB1) (2). Mutations in the retinal pigment epithelium–specific protein 65 kDa (RPE65) gene account for 5%–10% of all LCA cases (2, 3). RPE65 is highly expressed in the retinal pigment epithelium (RPE), where it encodes a retinoid isomerase enzyme essential for the production of chromophore, which forms the visual pigment in the rod and cone photoreceptors of the retina. Interestingly, the LCA-associated genes encode proteins with a wide variety of retinal functions, such as photoreceptor morphogenesis, phototransduction, vitamin A cycling, guanine synthesis, and outer segment (OS) phagocytosis (Figure ​(Figure1).1). Recently, several mutations were identified that are likely to affect intraphotoreceptor ciliary transport processes.

Open in a separate window

Figure 1

Spatial expression of the proteins encoded by LCA-associated genes.

RPE65 and LRAT are located in the membranes of RPE cell endoplasmic reticulum. CEP290 is located in the basal bodies of rod and cone photoreceptors. Lebercilin, CEP290, and RPGRIP1 have prominent localization in the photoreceptor CC. GUCY2D localizes to the OS disc membranes of rod and cone photoreceptors. PDE, phosphodiesterase. Adapted with permission from Progress in Retinal and Eye Research (2).

Although nearly all identified LCA-associated genes are expressed preferentially or specifically in the retina, two genes recently identified as mutated in patients with LCA, CEP290 (4) and LCA5 (which encodes Lebercilin; ref. 5), are ubiquitously expressed. Furthermore, the identification of these genes as LCA associated highlights the important role of ciliary proteins in the pathogenesis of LCA, as has been observed for other retinal dystrophies (e.g., Bardet-Biedl and Usher syndromes). Mutation analysis in a French Canadian family identified an intronic mutation, c.2991+1655A>G (p.C998X), that results in the insertion of a cryptic exon in the CEP290 mRNA and introduces a premature stop codon in the protein. Strikingly, this mutation was found in 20% of LCA patients, rendering it one of the most important causes of LCA to date (4).

The diagnosis of LCA is based on clinical findings. Identification of the genetic cause by molecular genetic testing is important to both distinguish LCA from other retinal diseases and give a patient a more accurate visual prognosis based on genotype-phenotype correlations.

In this issue of the JCI, two independent research groups report significant new data on the molecular pathogenesis of LCA and on the potential of gene therapy in individuals with selected LCA-causing gene defects. Boldt et al. demonstrate a direct involvement of defective intraflagellar transport (IFT) in LCA and provide evidence that Lebercilin functions as an integral element of selective protein transport through photoreceptor cilia (6). Ashtari et al. demonstrate stable retinotopic functional improvement in humans after retinal gene therapy, as reflected by responses of the visual cortex (7).

Some mechanisms implicated in the pathogenesis of LCA

The mechanisms underlying LCA are multiple and not fully understood. Despite the striking genetic heterogeneity, the main clinical features of LCA can be categorized into a more limited number of phenotypes, a fact that points toward overlapping pathogenic disease mechanisms. Emerging data suggest that one of these possible mechanisms may affect transport across the photoreceptor connecting cilium (CC) — the sole link between the inner segment (IS) and OS of photoreceptors. As the photoreceptor IS (containing the metabolic machinery of the cell) and the OS (membranous disks containing phototransduction proteins) are linked solely by a CC, correct transport of proteins through the CC is crucial for the function and maintenance of the cell (Figure ​(Figure2).2). Boldt et al. analyze how mutations in the LCA5 gene affect the connectivity of the encoded protein, Lebercilin, and provide evidence that Lebercilin functions as an integral element of selective protein transport through the photoreceptor CC (6). This study represents the first molecular confirmation that disrupted IFT — an elaborate mechanism that mediates the polarized trafficking of proteins required for efficient phototransduction — is directly implicated in LCA. The primary cilium of photoreceptors mediates polarized trafficking of proteins for efficient phototransduction. During ciliogenesis, protein complexes are transported distally for growth of the axoneme using IFT (8). Since proteins and protein precursors are transported across the ciliary compartments via IFT, mutations in genes encoding proteins that participate in IFT can cause a spectrum of different ciliopathies.

Open in a separate window

Figure 2

Photoreceptor CC.

Cilia consist of a backbone (or axoneme), which contains microtubule doublets arranged in a circle. The cilium is anchored in the basal body, which regulates and organizes microtubule assembly. The photoreceptor CC is a specialized primary (nonmotile) cilium. It connects the photoreceptor IS, which contains the metabolic machinery of the cell, and the OS, which contains the photosensitive apparatus. As the OS is unable to synthesize proteins and lipids, the CC has an important role in transport from the IS to the OS. RPGR, retinitis pigmentosa GTPase regulator.

Advances in therapy for LCA

Ocular gene therapy has been tried with success in mice, dogs, and, most recently, humans (15). It is most advanced for LCA caused by mutations in RPE65. Proof of principle for gene therapy came from studies in Briard dogs, a naturally occurring model of retinal degeneration resulting from mutations in RPE65 (16). Gene therapy using adeno-associated virus–mediated (AAV-mediated) delivery of RPE65 was shown to restore visual function in Briard dogs (16), with sustained success over many years in 95% of treated eyes (17). The results of three simultaneous phase I clinical treatment trials of AAV-mediated RPE65 gene therapy in humans (18, 19) demonstrated safety and showed slight improvement in vision in both bright and dim light. Clinical data on more than 30 patients are now available, showing stable clinical benefit in all patients, with no severe adverse effects (20, 21).

Ashtari et al. studied how the visual cortex responds to recovery of retinal function after prolonged sensory deprivation and provided the spectacular initial evidence that the visual cortex can be made responsive to visual input even after prolonged visual deprivation (up to 35 years; ref. 7). This study sheds light on the still-unanswered question concerning the Molyneux debate. More than 300 years ago, Molyneux formulated a problem as to “whether a man who has been born blind and who has learnt to distinguish and name a globe and a cube by touch, would be able to distinguish and name these objects simply by sight, once he had been enabled to see” (22). For modern neuroscientists, the answer to this question has an important bearing on contemporary issues concerning crossmodal identification and intermodal interactions — in other words, how the brain integrates information from the different senses. The results from the work of Ashtari et al. have a substantial effect on our understanding of the capacities of the visual cortex to be reactivated after visual deprivation. The study involved individuals with LCA2, a form of LCA caused by mutations in RPE65, who were injected unilaterally with AAV carrying normal RPE65 cDNA (AAV2-hRPE65v2) in their worst-seeing eye. Using psychophysical testing and functional MRI (fMRI) 1 year after the injection, Ashtari et al. provided an excellent demonstration that gene augmentation therapy in humans with LCA2 rendered both the retina and the visual cortex far more sensitive to dimmer light and lower-contrast stimuli (7). Cortical activation was found in regions corresponding to the area of the retina that had been exposed to AAV2-hRPE65v2, and the topography corresponded to visual field improvement. This is the first demonstration of stable, retinotopic improvement in humans for at least 2 years after retinal gene therapy, reflected by response of the visual cortex. The fMRI finding that the visual cortex can be reawakened after chronic visual deprivation in a rare eye disease may have much broader implications, providing promise for the outcome of gene therapy for both early- and late-onset retinal degenerative diseases.

Translating genotypic and phenotypic insights into major therapeutic advances

Considering the clinical heterogeneity of LCA (24), a detailed genotype-phenotype correlation analysis is critical in order to understand the progression and pathogenesis of this devastating eye disease, as illustrated by the study by Boldt et al. on Lebercilin (6). Further elucidation of the molecular mechanisms of LCA in the retina and development of gene therapy approaches for different genetic subtypes of the disease are required. In particular, the status of remaining photoreceptors at the time of treatment will represent the most predictive parameter in terms of functional improvement. Moreover, the age of onset of profound visual impairment will determine the development of the visual cortex in the early years during the critical period. As LCA2 often spares significant visual function in the early years, sometimes into the second decade, this may represent a privileged situation for gene therapy: photoreceptors are affected secondary to RPE dysfunction, and cortical stimulation by formed images has occurred during the critical period, prior to the advent of legal blindness. The report by Ashtari et al. on cortical function restoration after therapy (7) brings great promise. Depending on the affected gene and severity of the phenotype, the extension of the landmark achievements in LCA2 to other types of LCA may prove more challenging depending upon the age of intervention.

Acknowledgments

Footnotes

References